JTE-162

N/A

Report date: 2026/02/10 20:00:22
NME

Base Information

Drug NameJTE-162
Drug Alias NameJTE-162
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNACHT, LRR and PYD domains-containing protein 3 inhibitors
TargetsNACHT, LRR and PYD domains-containing protein 3
Therapy Area/IndicationsInflammationAutoimmune DiseasesCryopyrin-Associated Periodic Syndromes
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesJt Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAkros Pharma Inc
Inactive CompaniesN/A
Active IndicationsInflammationAutoimmune DiseasesCryopyrin-Associated Periodic Syndromes
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A